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DemyelinationAutoantibodies against the water channel AQP4, expressed predominately in central nervous system astro-
cytes, are markers and pathogenic factors in Devic's disease. In this study we examined whether Multiple
Sclerosis (MS) patients recognize antigenic epitopes on AQP4 that may deﬁne distinct disease subsets.
We screened sera from 45 patients with relapsing–remitting MS (RRMS) and 13 patients with primary pro-
gressive MS (PMS). 23 Neuromyelitis Optica (NMO) patients previously characterized were used as assay
positive/negative controls. Sera from 23 patients with Systemic Lupus Erythematosus, 23 with primary Sjogren
syndrome without neurological involvement and from 28 healthy individuals were also used as controls.
NMO-positive sera exhibited reactivity against the intracellular epitope AQPaa252-275, conﬁrming previous
observations. All RRMS sera tested negative for anti-AQP4 antibodies using a cell-based assay, but surprisingly,
13% of them reacted with the epitope AQPaa252-275. PMS, healthy and disease controls showed no speciﬁc
reactivity. Whether these antibodies deﬁne distinct MS subsets and have a pathogenic potential pointing to
convergent pathogenetic mechanism with NMO, or are simply markers of astrocytic damage, remains to be
determined.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Multiple sclerosis (MS) is a chronic debilitating autoimmune dis-
ease of the central nervous system. It is considered a T-cell orchestrat-
ed disorder, although signiﬁcant evidence supports the notion that
B-cell autoimmunity is an important contributor. Histopathological
studies have shown the existence of B-cell mediated type II MS
(Lucchinetti et al., 2000) and serological studies have described a
number of autoantibodies, the most typical being the antibodies
against MOG and the most recent being the antibodies against ion
channel Kir4.1 (Srivastava et al., 2012). In contrast, in Neuromyelitis
optica (NMO) or Devic's disease the main pathogenetic factor is the an-
tibodies against AQP4, a water channel mainly expressed in astrocytes
(Lennon et al., 2005). On the basis of distinct pathogenetic mechanisms,
MS andNMOare considered different disease entities, despite certain ra-
diological and clinical similarities as well as some recent overlapping
data that cloud the disease boundaries (Bruck et al., 2012; Siritho et al.,
2011). The suggestion that there may be clinical intermediate typesogy Unit, Department of Path-
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rights reserved.within the spectrumof NMO andMS subsets, prompted us to investigate
whether we could detect signs of NMO autoimmunity in typical MS pa-
tients. A sensitive ELISA method, recently developed by our group
(Kampylafka et al., 2011) to describe the dominant B-cell linear epitopes
in NMO-AQP4 positive patients, was employed.
2. Methods
2.1. Patients and sera
Sera was tested from 45 patients with relapsing–remitting MS
(RRMS) and 13 patients with primary progressiveMS (PMS) diagnosed
according to McDonald criteria. 23 patients positive for anti-AQP4 anti-
bodies were selected using a commercially available cell based assay
(Euroimmun, Luebeck, Germany). Sera from 28 healthy subjects were
used as normal controls. The disease control group comprised of 23 pa-
tients with Systemic Lupus Erythematosus (SLE) fulﬁlling the 1997
American College of Rheumatology revised criteria for the classiﬁcation
of SLE (Hochberg, 1997) and 23 patients with primary Sjögren's
Syndrome, without neurological involvement fulﬁlling the American–
European Consensus Group revised criteria (Vitali et al., 2002).
2.2. Peptide synthesis
Peptides were synthesized as previously described (Kampylafka
et al., 2011). Brieﬂy, eleven peptides in the form of peptide dendrimers
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Inc., U.S.A. Three peptides, previously shown to be the main linear
target epitopes of AQP4 autoantibodies, were selected for the present
study. AQPpep1 (aa 1-22, MSDRPTARRWGKCGPLCTRENI) has been
designed to include the ﬁrst 22 amino acids that are included only in
the M1 isoform of the aquaporin 4 protein. AQPpep4 (aa 88-113,
FGHISGGHINPAVTVAMVCTRKISIA) corresponds to theﬁrst intracellular
loop of the molecule while AQPpep8 (aa 252-275, FCPDVEFKRRF
KEAFSKAAQQTKG) represents a key epitope in the C-terminus intracel-
lular domain.
2.3. ELISA-AQP4 assays
All patients and controls were evaluated for the presence of auto-
antibodies against the selected peptides by ELISA assays. 96-well mi-
crotitre plates were coated with 100 μl of peptide solution (2.5 μg/ml
in sodium carbonate–sodium bicarbonate buffer, pH 9.8) and kept at
4 °C overnight. Afterwards, the remaining binding sites were blocked
with 2% bovine serum albumin (BSA) in phosphate buffered saline
(PBS) at room temperature for 1 hour. After 3 washes with PBS,
sera were added in 1/150 in 2% BSA/PBS dilution. After a 2-hour incu-
bation and 3 washes with PBS, alkaline phosphate conjugated anti-
human IgG, diluted 1/1200 in 2% BSA/PBS, was added for 1 hour
at room temperature and color development was quantiﬁed at
405 nm. The cut-off values for each peptide assay were determineda) NMO patient
b) RRMS patient
c) ELISA 
d) MS serum #37 e
Fig. 1. All patients included in the study were initially tested for the presence of anti-AQP4
romyelitis Optica patient, scale 200 μm. (b) All Multiple Sclerosis (MS) patients included in
were tested by ELISA against AQPpep8 (aa 252–275 of the AQP4 molecule). MS positive se
serum exhibiting speciﬁc binding. (e) An example of a serum exhibiting non-speciﬁc bindiusing the mean Optical Density plus 3 standard deviations of the
sera from the 28 healthy controls.
Homologous inhibition experiments were performed, in order to
evaluate the speciﬁcity of the binding. These assays were initially
performed with variations of serum and peptide concentrations in pre-
treatment dilutions, in order to deﬁne the relative concentrations that
would provide optimal results. The rest of the ELISA conditions (i.e. tem-
perature, duration of incubation, diluting andwashing buffers) remained
the same. In this context, serumdilutions of 1/150, 1/300 and 1/500were
each combinedwith peptide concentrations of 0–4–16–64 μg/ml and 0–
10–40 μg/ml, in order to deﬁne optimal conditions. An inhibition assay
was considered to be positive when the inhibition percentages for the
examined peptide were ≥50%, and the reactivity range between the
examined peptide and the control peptide was ≥40%. Following assay
optimization all positive MS and control sera were tested. Serum was
pretreated in 1/300 dilution with increasing concentrations (0 μg/ml,
10 μg/ml and 40 μg/ml) of reactive peptide and control peptide
(Ctrl-Pep) and incubated overnight at 4 °C. Subsequently, all sera dilu-
tions were tested by ELISA for reactivity against the peptides.
2.4. ELISA-MOG assays
All MS patients and healthy controls were tested for the presence
of anti-MOG serum antibodies using a commercial ELISA SensoLyte®
anti-Human MOG IgG kit following the manufacturer's instructions.assay
) MS serum #19
antibodies using a ﬂuorescent cell based assay. (a) A representative staining for a Neu-
the study, tested negative for anti-AQP4 antibodies in the cell-based assay. (c) All sera
ra in our ELISA were tested for speciﬁcity using inhibition assays. (d) An example of a
ng.
Table 1
Patient clinical and laboratory characteristics.



















MS9 F 19 3 2 1 5.3 Yes Yes Yes Positive Yes
MS24 F 30 6 0 1 6.9 Yes No Yes Positive Yes
MS37 F 44 5 1 Unknown 0.5 Yes Yes Yes Positive Yes
MS39 F 30 8 1 1 0.3 Yes Yes No Positive Yes
MS46 F 26 7 2 3,5 3.4 Yes No Yes Positive Yes
MS60 F 18 8 Unknown 6 2.1 Yes Yes Yes Positive Yes
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NMO-positive sera, selected by a cell-based assay, exhibited spe-
ciﬁc reactivity (as attested by the homologous inhibition experi-
ments) against intracellular epitope AQPaa252–275, conﬁrming
previous work. As expected, RRMS and PMS sera tested negative for
anti-AQP4 antibodies using a ﬂuorescent cell-based assay (Fig. 1b).
The same sera however tested by ELISA, showed that 8/45 patients
reacted (cut-off >3SD of the healthy controls) with the peptide
AQPaa252–275 (Fig. 1c). Following homologous inhibition experi-
ments, it was shown that the reaction was speciﬁc in 6/8 patients
(13% speciﬁc reactivity in the RRMS group). (Examples of a positive
and a negative inhibition assay are shown in Fig. 1d and e, respec-
tively) No speciﬁc reaction was observed in the RRMS group for the
other two peptides tested (AQP aa 1–22, AQP aa 88–113). PMS,
healthy and disease controls showed no speciﬁc reactivity against
any of the AQP4 peptides.
All MS patients were also tested for anti-MOG reactivity using
ELISA. Our rationale was to test whether our sera were polyreactive,
i.e. binding variable antigenic targets. Only one RRMS patient showed
positivity higher than 3 standard deviations of the mean of the
healthy controls (Supplementary Fig. 1).
3.1. Clinico-pathological correlations
All six AQP4-positive RRMS patients were women with a variant
age of disease onset (18–44 years old) and disease duration from 3
to 8 years. They were all diagnosed according to the MacDonald
criteria, with dispersion in both time and space. All patients had
optic neuritis, positive IgG index, oligoclonal CSF bands and MRI
ﬁndings consistent with MS in the brain and cervical spinal cord.
Four patients also had ﬁndings in the thoracic spinal cord (Table 1).
4. Discussion
We demonstrate that a subset of RRMS patients (13%) have anti-
bodies against the C-terminal of the AQP4 molecule; none of the pa-
tients with RRMS or PMS have antibodies to structural AQP4
epitopes based on a cell-based assay.
A discrepancy was noted between two recent studies; in one, a
percentage of classic MS patients harbored anti-AQP4 antibodies
based on a cell-based assay, but in a follow-up study in the same
ethnic group (Apiwattanakul et al., 2012), no AQP4 positivity was
shown, arguing that the NMO spectrum of diseases needs better clin-
ical clariﬁcation. Our results support the view that even among Cau-
casian patients with classic MS, a subset of patients with RRMS
exhibits immunological overlap with NMO regarding certain antigen-
ic epitopes on the AQP4 molecule.
To identify whether there were any clinical commonalities
between the C-terminal- AQP4 -positive RRMS patients and the
NMO-disease spectrum, we retrospectively examined the medical re-
cords of the positive RRMS patients. We observed that, a common
clinical ﬁnding in all six positive patients was that their ﬁrst clinical
manifestation was optic neuritis. Of special interest, ﬁve of the six
patients had not responded in immunomodulatory treatments andhad to switch to immunosuppressive therapy with a good clinical
outcome after 3–8 years of follow up and an EDSS score for all 6
patients between 0 and 2.5.
What is particularly pertinent to NMO, is the observation that the
N-terminal domain where the main B-cell epitope resides, is in an
area where a signiﬁcant T-cell epitope is also found (Arellano et al.,
2012). In NMO patients, this T-cell epitope resides at amino acids
281–300 adjacent to the most prominent B-cell linear epitope which
resides at amino acids 252–275 (Kampylafka et al., 2011). Because
both of these epitopes are intracellular and were not found in any
other disease tested, the results suggest that in NMO, contrary to the
common belief that only the extracellular epitopes are important for
disease progression, some extracellular domains may be also relevant,
at least in pointing out antigenic similarities between NMO and RRMS
patients.
It is still unclear how these prominent intracellular epitopes contrib-
ute to NMO pathogenesis and whether the presence of speciﬁc antibo-
dies against them plays a role in the pathogenesis of MS. In NMO
lesions, complement activation products are found within astrocytes
and macrophages, resembling type-II MS lesions (Bruck et al., 2012)
Of interest, antibody-independent AQP4 loss, is observed in MS lesions
(Matsuoka et al., 2011), suggesting that an astrocytopathy is maybe a
feature in someMS patients (Kira, 2011). It is possible, that the affected
astrocytes in these MS cases, may release otherwise cryptic epitopes
which are then recognized by the immune system, as proposed for
several systemic autoimmune diseases (i.e.Lupus) (Routsias et al.,
2006). Likewise, it can be hypothesized that in NMO both T- and B-
cell intracellular epitopes may be periodically exposed after the initial
astrocytic damage, thereby contributing to sudden relapses. As the fac-
tors that trigger a relapse inMS patients remain unknown, the proposed
hypothesis that AQP4 epitopes are exposed during astrocytic damage
might be also applicable to MS. It is notable however, that our observa-
tions were speciﬁc for the RRMS, as none of the patients with PMS or
any of the other autoimmune disease controls tested, such as SLE or
Sjogren's syndrome, which often associated with NMO, recognized the
C-terminal AQP-4 epitope. Also, the positive RRMS patients did not rep-
resent a polyreactivity phenomenon because they did not recognize
other relevant antigenic targets such as MOG. Further work is needed
to elucidate the pathogenic signiﬁcance of these antibodies.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.jneuroim.2013.04.017.References
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